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Tubuloglomerular 
feedback and 
adenosine
Tubuloglomerular feedback is an 
enigmatic process whereby the 
glomerular fi ltration rate is regulated 
by tubular reabsorption in the same 
nephron. Increased fl uid delivery or 
reabsorption in the macula densa leads 
to a reduced fi ltration rate. As you can 
imagine, direct demonstration requires 
perfusion of the tubule, with known 
solutions and measurement of the 
fi ltration rate or arteriolar diameter 
in the same isolated preparation — a 
feat only a few scientists are capable 
of. But, in the age of knockout mice, 
these studies have suddenly started 
to generated molecular answers. It is 
known that macula densa cells release 
adenosine triphosphate (ATP) in 
response to increased tubular sodium 
chloride (NaCl) delivery. But what 
happens to the ATP aft er that? Is ATP 
the mediator of the eff ect, or does ATP 
get degraded to adenosine, which is the 
fi nal mediator of arteriolar constriction? 
As they report in this issue, Ren et al. 
increased NaCl concentration in the 
macula densa and found that the eff erent 
arteriole dilated, but that this dilatation 
was blocked by specifi c blockers of 
adenosine receptors. When perfusion 
with hexokinase increased adenosine 
by resynthesis of ATP from adenosine 
diphosphate, it potentiated small 
changes in NaCl. Th ese results, which 
are discussed in a nice Commentary by 
Blantz and Vallon (page 837), show the 
primacy of adenosine in the mediation 
of tubuloglomerular feedback. See page 
861.
Prevalence of ESRD 
among the Navajo
Th e Navajo Nation has 200,000 members 
and is a well-studied group. It is well 
known that Navajos are at high risk for 
diabetes mellitus, but the incidence of 
end-stage renal disease (ESRD) is less 
established. In a new article, Hochman 
et al. present an estimation of the burden 
of ESRD in this population. Th ey used 
the data from the United States Renal 
Data System to estimate the prevalence 
and incidence of ESRD among all 
Native American adults, all US adults, 
and Native American adults living 
in the same region. Both prevalence 
and incidence of ESRD among Native 
American adults on the Navajo Nation 
were higher than those among US adults 
and among Native American adults in 
the US, but lower than those among 
other Native American adults in the 
Southwest. Th e reasons behind these 
surprising fi ndings require more study. 
See page 931.
Tacrolimus in 
membranous 
nephropathy
Membranous nephropathy is a common 
cause of nephrotic syndrome in adults 
whose natural history is variable; some 
patients’ renal function deteriorates 
inexorably, whereas others’ achieves 
spontaneous remission. Th is variability 
has led to diffi  culties in demonstrating 
effi  cacy of various treatment regimens. 
In their recent study, Praga et al. 
conducted a prospective, randomized, 
clinical trial testing treatment in these 
patients for 1 year, followed by a slow 
taper. Th e probability of remission 
in the treated group was higher than 
in the control group by a signifi cant 
margin. By 18 months, almost all treated 
patients had a remission with reduced 
proteinuria, whereas only one-third 
of the control group did so. Of the 25 
treated patients, the serum creatinine 
level doubled in only one patient, 
whereas serum creatinine doubled in 
6 of the 23 controls over the period of 
observation. While no patient had a 
relapse on tacrolimus taper, nephrotic 
syndrome reappeared in almost half 
of the patients aft er drug withdrawal. 
Th is impressive result is discussed in 
an accompanying Commentary by Lai 
(page 841) that sets these issues in their 
therapeutic context. See page 924.
